By VC News Daily
FARMINGTON, CT, LambdaVision, an innovative biotech company, announced it secured the first closing of its seed round being led by Aurelia Foundry Fund.
LambdaVision, an innovative biotech company developing a protein-based artificial retina to help patients regain sight lost to retinal degenerative diseases, announced it secured the first closing of its seed round being led by Aurelia Foundry Fund, a fund spun out of MIT. The round also includes investment from Boryung, a publicly listed Korean pharmaceutical company, and E2MC Ventures.
(c) by Massinvestor, Inc. For contact info, please check out our about page.